Ubs Asset Management Americas Inc Aprea Therapeutics, Inc. Call Options Transaction History

Ubs Asset Management Americas Inc

  • $381 Billion
  • Q3 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding APRE

# of Institutions
2
Shares Held
899
Call Options Held
0
Put Options Held
0
View Full List

About Aprea Therapeutics, Inc.

APRE Quotes by TradingView
  • Ticker APRE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Description
  • Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...
More about APRE
Track This Portfolio

Track Ubs Asset Management Americas Inc Portfolio

Follow Ubs Asset Management Americas Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email